CapricorCAPR
NASDAQ製藥
US$8.37+0.00%
關鍵指標
$2.04B市值
US$40.3752 週最高
US$4.3052 週最低
1,165,11330 日均量
231 員工數57.84M 流通股本上市日期 2002-06-20
下次財報 ~2026年2月2日
關於 Capricor
Capricor Therapeutics Inc 是一家臨床階段的生物技術公司，專注於開發用於治療杜氏肌萎縮症 (DMD)（一種導致肌肉退化和早逝的罕見肌萎縮症）和其他具有高未滿足醫療需求的疾病的轉型性細胞和外泌體基質療法。該公司的產品管線包括 CAP-1002，一種異體心臟衍生細胞療法 deramiocel。Deramiocel 目前正進入杜氏肌萎縮症治療的第三期臨床開發階段。透過其專有的 StealthXTM 平台，該集團利用其外泌體技術進行專注於疫苗學、遞送寡核苷酸、蛋白質和用於治療的小分子的臨床前研究。
最新新聞
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kirby McInerney LLP Alerts Investors Who Acquired Capricor Therapeutics, Inc. CAPR Securities Between December 17, 2025 and July 26, 2026 of Pending Lawsuit
NASDAQ: CAPR LAWSUIT ALERT: Investors who lost money with shares of Capricor Therapeutics, Inc.should contact the Shareholders Foundation
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
CAPR Court Alert: Capricor Therapeutics Securities Fraud Class Action Deadline is Approaching on September 28 for Investors that Suffered Losses
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
相關股票製藥 產業
想看 CAPR 的即時 AI 觀點嗎?
啟動即時多智能體分析室 — Claude、GPT、Gemini、DeepSeek、Grok 和 Qwen 同時分析 CAPR,即時輸出訊號。